Patient-reported outcomes of neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) trial – a phase II trial

Patient Reported ◽

Initial patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) trial

10.1016/s1569-9056(19)31014-0 ◽

2019 ◽

Vol 18 (1) ◽

pp. e1402

Author(s):

X.Y. Yang ◽

E.J. Aslim ◽

K. Chen ◽

T.W. Chong ◽

J.S.P. Yuen ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Radical Prostatectomy ◽

Phase Ii ◽

Patient Reported Outcomes ◽

Patient Reported ◽

Neoadjuvant apalutamide (arn-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) – initial results of a phase II trial

10.1016/s1569-9056(19)31008-5 ◽

2019 ◽

Vol 18 (1) ◽

pp. e1394

Author(s):

E.J. Aslim ◽

X. Yang ◽

N-T. Ngo ◽

L.Y. Khor ◽

K. Chen ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Radical Prostatectomy ◽

Phase Ii ◽

Phase Ii Trial ◽

Risk Prostate Cancer ◽

Initial Results

138 ADJUVANT MULTIMODALITY TREATMENT IN PATIENTS WITH HIGH RISK PROSTATE CANCER FOLLOWING RADICAL PROSTATECTOMY: RESULTS OF A PROSPECTIVE CLINICAL PHASE-II TRIAL

10.1016/s1569-9056(07)60137-7 ◽

2007 ◽

Vol 6 (2) ◽

pp. 57

Author(s):

A. Heidenreich ◽

C. Ohlmann ◽

D. Pfister ◽

D. Thüer ◽

U.H. Engelmann

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Radical Prostatectomy ◽

Phase Ii ◽

Phase Ii Trial ◽

Multimodality Treatment ◽

Clinical Phase ◽

Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer

BJU International ◽

10.1111/bju.12676 ◽

2015 ◽

Vol 116 (1) ◽

pp. 50-56 ◽

Cited By ~ 10

Author(s):

Jonathan L. Silberstein ◽

Stephen A. Poon ◽

Daniel D. Sjoberg ◽

Alexandra C. Maschino ◽

Andrew J. Vickers ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Radical Prostatectomy ◽

Phase Ii ◽

Phase Ii Trial ◽

Chemohormonal Therapy ◽

Oncological Outcomes ◽

Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer

BJU International ◽

10.1111/j.1464-410x.2007.06760.x ◽

2007 ◽

Vol 100 (2) ◽

pp. 274-280 ◽

Cited By ~ 54

Author(s):

Tomaso Prayer-Galetti ◽

Emilio Sacco ◽

Francesco Pagano ◽

Marina Gardiman ◽

Antonio Cisternino ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Radical Prostatectomy ◽

Phase Ii ◽

Phase Ii Trial ◽

Risk Prostate Cancer ◽

Long Term Follow Up

MP79-05 NEOADJUVANT APALUTAMIDE (ARN-509) AND RADICAL PROSTATECTOMY IN TREATMENT OF INTERMEDIATE TO HIGH RISK PROSTATE CANCER (NEAR) PHASE II TRIAL

The Journal of Urology ◽

10.1097/ju.0000000000000971.05 ◽

2020 ◽

Vol 203 ◽

pp. e1216-e1217

Author(s):

XinYan Yang* ◽

Edwin Jonathan Aslim ◽

Nye Thane Ngo ◽

Li Yan Khor ◽

Tsung Wen Chong ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Radical Prostatectomy ◽

Phase Ii ◽

Phase Ii Trial ◽

Patient-Reported QOL Outcomes of Hypofractionated Stereotactic Body Radiation Therapy Boost for the Treatment of Localized, Non-Metastatic, High-Risk Prostate Cancer: Updated Results of a Phase II Trial

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2020.07.533 ◽

2020 ◽

Vol 108 (3) ◽

pp. e907-e908

Author(s):

K. Cheng ◽

M.M. Qureshi ◽

M.A. Dyer ◽

B.N. Bloch ◽

G. Gignac ◽

...

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

High Risk ◽

Phase Ii ◽

Stereotactic Body Radiation Therapy ◽

Phase Ii Trial ◽

Stereotactic Body Radiation ◽

Patient Reported ◽

MP22-19 NEOADJUVANT APALUTAMIDE (ARN-509) AND RADICAL PROSTATECTOMY IN TREATMENT OF INTERMEDIATE TO HIGH RISK PROSTATE CANCER (NEAR)–INITIAL RESULTS OF A PHASE II TRIAL

The Journal of Urology ◽

10.1097/01.ju.0000555604.36690.b1 ◽

2019 ◽

Vol 201 (Supplement 4) ◽

Author(s):

Edwin Jonathan Aslim ◽

XinYan Yang* ◽

Nye-Thane Ngo ◽

Li Yan Khor ◽

Kenneth Chen ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Radical Prostatectomy ◽

Phase Ii ◽

Phase Ii Trial ◽

Risk Prostate Cancer ◽

Initial Results

NEOADJUVANT CHEMOHORMONAL TAXANE-BASED THERAPY BEFORE RADICAL PROSTATECTOMY (RRP) IN HIGH-RISK PROSTATE CANCER: 4.4 YEARS' FOLLOW-UP OF A PHASE II TRIAL

10.1016/s1569-9056(06)60771-9 ◽

2006 ◽

Vol 5 (2) ◽

pp. 214

Author(s):

T. Prayer-Galetti ◽

P. Sperandio ◽

M. Gardiman ◽

V. De Marco ◽

A. Cisternino ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Radical Prostatectomy ◽

Phase Ii ◽

Phase Ii Trial ◽

Neoadjuvant IMC-A12 and combined androgen deprivation with prostatectomy for high-risk prostate cancer: A phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps251 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS251-TPS251 ◽

Cited By ~ 3

Author(s):

J. P. Dean ◽

S. R. Plymate ◽

B. L. Dalkin ◽

W. J. Ellis ◽

D. W. Lin ◽

...

Keyword(s):

Prostate Cancer ◽

High Risk ◽

Phase Ii ◽

Phase Ii Trial ◽

Androgen Deprivation ◽